These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 31694630)

  • 1. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
    Dieckmeyer M; Ruschke S; Rohrmeier A; Syväri J; Einspieler I; Seifert-Klauss V; Schmidmayr M; Metz S; Kirschke JS; Rummeny EJ; Zimmer C; Karampinos DC; Baum T
    BMC Musculoskelet Disord; 2019 Nov; 20(1):515. PubMed ID: 31694630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Vertebral Marrow Fat Fraction Using 3D Fat Analysis & Calculation Technique Imaging Sequence in Aromatase Inhibitor-Treated Breast Cancer Women.
    Wan T; Zhu Y; Han Q; Liu L
    Front Endocrinol (Lausanne); 2022; 13():931231. PubMed ID: 35813643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Texture analysis of vertebral bone marrow using chemical shift encoding-based water-fat MRI: a feasibility study.
    Burian E; Subburaj K; Mookiah MRK; Rohrmeier A; Hedderich DM; Dieckmeyer M; Diefenbach MN; Ruschke S; Rummeny EJ; Zimmer C; Kirschke JS; Karampinos DC; Baum T
    Osteoporos Int; 2019 Jun; 30(6):1265-1274. PubMed ID: 30903208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
    María RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
    Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical Shift-Encoded MRI of the Lumbar Vertebral Bone Marrow for Detecting Osteoporosis With Low Trabecular Bone Quality in Patients With Breast Cancer Receiving Aromatase Inhibitors.
    Misaka T; Hashimoto Y; Ashikaga R; Ishida T
    J Magn Reson Imaging; 2024 Jan; ():. PubMed ID: 38174771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Texture Analysis Using CT and Chemical Shift Encoding-Based Water-Fat MRI Can Improve Differentiation Between Patients With and Without Osteoporotic Vertebral Fractures.
    Sollmann N; Becherucci EA; Boehm C; Husseini ME; Ruschke S; Burian E; Kirschke JS; Link TM; Subburaj K; Karampinos DC; Krug R; Baum T; Dieckmeyer M
    Front Endocrinol (Lausanne); 2021; 12():778537. PubMed ID: 35058878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of incidental vertebral fractures and longitudinal changes of MR-based proton density fat fraction and T2* measurements of vertebral bone marrow.
    Leonhardt Y; Ketschau J; Ruschke S; Gassert FT; Glanz L; Feuerriegel GC; Gassert FG; Baum T; Kirschke JS; Braren RF; Schwaiger BJ; Makowski MR; Karampinos DC; Gersing AS
    Front Endocrinol (Lausanne); 2022; 13():1046547. PubMed ID: 36465625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vertebral Bone Marrow Heterogeneity Using Texture Analysis of Chemical Shift Encoding-Based MRI: Variations in Age, Sex, and Anatomical Location.
    Dieckmeyer M; Junker D; Ruschke S; Mookiah MRK; Subburaj K; Burian E; Sollmann N; Kirschke JS; Karampinos DC; Baum T
    Front Endocrinol (Lausanne); 2020; 11():555931. PubMed ID: 33178134
    [No Abstract]   [Full Text] [Related]  

  • 9. Measurement of vertebral bone marrow proton density fat fraction in children using quantitative water-fat MRI.
    Ruschke S; Pokorney A; Baum T; Eggers H; Miller JH; Hu HH; Karampinos DC
    MAGMA; 2017 Oct; 30(5):449-460. PubMed ID: 28382554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
    J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
    Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
    Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of gestational diabetes and proton density fat fraction of vertebral bone marrow and paraspinal musculature in premenopausal women.
    Harada S; Gersing AS; Stohldreier Y; Dietrich O; Lechner A; Seissler J; Ferrari U; Pappa E; Hesse N
    Front Endocrinol (Lausanne); 2023; 14():1303126. PubMed ID: 38292769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women: The ADIMOS Case-Control Study.
    Paccou J; Badr S; Lombardo D; Khizindar H; Deken V; Ruschke S; Karampinos DC; Cotten A; Cortet B
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2526-2536. PubMed ID: 37017011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR-based proton density fat fraction (PDFF) of the vertebral bone marrow differentiates between patients with and without osteoporotic vertebral fractures.
    Gassert FT; Kufner A; Gassert FG; Leonhardt Y; Kronthaler S; Schwaiger BJ; Boehm C; Makowski MR; Kirschke JS; Baum T; Karampinos DC; Gersing AS
    Osteoporos Int; 2022 Feb; 33(2):487-496. PubMed ID: 34537863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
    Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
    Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
    Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.
    Su G; Xiang Y; He G; Jiang C; Li C; Yan Z; Zhong Y
    Arch Med Res; 2014 Oct; 45(7):570-9. PubMed ID: 25450582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.